Nuclear Imaging in Drug Development — Introduction
The use of radioactive isotopes to generate images has developed in many directions to yield a series of sophisticated technologies with numerous applications in drug discovery and development. Imaging techniques now allow precise quantitative measurements to be made with high spatial resolution and ever improving time resolution. This brief introductory review will illustrate some of the practical applications of this technology to pharmaceutical research, using examples from our own laboratory which focuses on drug discovery and development in the CNS area. Repeated reference will be made to the applications of nuclear imaging to studies of the compound dizocilpine (1, MK-801), an antagonist of glutamate receptors of the N-methyl-D-aspartate (NMDA) subtype. This compound was first discovered as a novel anticonvulsant agent in our US laboratories more than a decade ago (Clineschmidt et al., 1982) and was later found to act as a potent noncompetitive NMDA antagonist (Wong et al., 1986). It has been found to be a powerful neuroprotective agent in a number of animal models of cerebral ischemia, which suggests the potential of NMDA antagonists for use in human cerebral ischemia, e.g., in the acute treatment of stroke (Iversen et al., 1989).
KeywordsPositron Emission Tomography Single Photon Emission Compute Tomography NMDA Antagonist Ischemic Hemisphere Drug Binding Site
Unable to display preview. Download preview PDF.
- Bowery NG, Wong EHF and Hudson AL (1988): Quantitative autoradiography of [3H]-MK-801 binding sites in mammalian brain. Br J Pharmac 93: 944–954.Google Scholar
- Hill DR, Campbell NJ, Shaw TM and Woodruff GN (1987): Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7: 2967–2976.Google Scholar
- Hill DR, Shaw TM, Graham W and Woodruff GN (1990): Autoradiographic detection of cholecystokinin-A receptors in primate brain using [125I]-Bolton Hunter CCK-8 and [3H]-MK-329. J Neurosci 10: 1070–1081.Google Scholar
- Iversen LL, Woodruff GN, Kemp JA, Foster AC, McKernan R, Gill R and Wong EHF (1989): Non-competitive NMD A antagonists as drugs. In: The NMDA Receptor, Watkins JC and Collingridge GL, eds. Oxford: IRL Press.Google Scholar
- McCulloch J (1982): Mapping functional alterations in the CNS with [14C]-deoxyglucose. In: Handbook of Psychopharmacology, Vol 15, Iversen LL, Iversen SD and Snyder SH, eds. New York: Plenum Press.Google Scholar